Stocks Health care DBVT
NASDAQ · Health careDBV Technologies S.A. (DBVT)
DBV Technologies S.A. brought in $4.9M of revenue over the twelve months to June 30, 2026, up 27.1% from a year earlier. It posted a net loss of $175.9M. In fiscal 2025 capital spending exceeded operating cash flow by $121.7M. At June 30, 2026 it held $174.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 16, 2026.
Watch DBVT in 60 secondsWhat DBV Technologies S.A. does
DBV Technologies S.A. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker DBVT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $5.6M | -$146.9M | -$1.05 | -$121.7M |
| 2024 | $4.2M | -$113.9M | -$1.17 | -$106.8M |
| 2023 | $15.7M | $72.7M | -$0.76 | -$80.3M |
| 2022 | $4.8M | $96.3M | -$1.24 | -$56.4M |
| 2021 | $5.7M | -$97.8M | -$1.78 | -$109.2M |
| 2020 | $11.3M | -$159.6M | -$2.95 | -$168.4M |
Full financial statements: income, balance sheet and cash flow
Where DBVT ranks in Health care
Latest SEC filings
What DBV Technologies S.A. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026Passive stake (5% or more) SCHEDULE 13G
- July 27, 2026
- July 16, 2026
- July 16, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 53% to $700K versus the same quarter last year; diluted EPS -$0.12 versus -$0.31.
- June 29, 2026Other event 8-K
- June 5, 2026
- June 4, 2026
- June 3, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running DBV Technologies S.A. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.3K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 29, 2026 | Mohideen PharisChief Medical Officer | Sold | 464 | $1.3K |
| January 29, 2026 | Mohideen PharisChief Medical Officer | Sold | 534 | $2.6K |
| December 18, 2025 | EPIC BpifranceMember of 10% owner group | Soldindirect | 1,292,103 | $5.4M |
| December 17, 2025 | EPIC BpifranceMember of 10% owner group | Soldindirect | 2,036,990 | $9.9M |
| December 17, 2025 | EPIC BpifranceMember of 10% owner group | Soldindirect | 40,000 | $211.2K |
| November 21, 2025 | Mohideen PharisChief Medical Officer | Sold | 1,624 | $4.5K |
| November 21, 2025 | Mohideen PharisChief Medical Officer | Received as pay | 44,000 | - |
| November 21, 2025 | Boucinha VirginieChief Financial Officer | Received as pay | 32,000 | - |
| November 21, 2025 | Trapp Kevin MichaelChief Commercial Officer | Received as pay | 55,000 | - |
| November 20, 2025 | Mohideen PharisChief Medical Officer | Sold | 6,496 | $18.7K |
Who owns DBVT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Baker Bros. Advisors LP13D, may seek influence with 3 related filers | 9.99% | January 14, 2026 |
| Suvretta Capital Management, LLC13G, passive with 2 related filers | 9.9% | April 11, 2025 |
| Janus Henderson Group PLC13G, passive | 8.8% | January 8, 2026 |
| Adage Capital Management, L.P.13G, passive with 2 related filers | 7.31% | May 13, 2026 |
| Raymond Debbane13G, passive with 7 related filers | 6.5% | May 5, 2026 |
| MPM BioImpact LLC13G, passive | 6.2% | August 14, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 5.8% | August 6, 2026 |
Largest institutional holders
Insiders
4 insiders reported holding 7,572,900 shares in total, about $88.1M at the last price.
| Holder | Shares |
|---|---|
| EPIC BpifranceMember of 10% owner group | 7,303,3697,303,369 held indirectly |
| Mohideen PharisChief Medical Officer | 144,531 |
| Boucinha VirginieChief Financial Officer | 70,000 |
| Trapp Kevin MichaelChief Commercial Officer | 55,000 |
Questions about DBVT
What does DBV Technologies S.A. do?
DBV Technologies S.A. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker DBVT.
Is DBV Technologies S.A. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $175.9M on revenue of $4.9M.
How much revenue does DBV Technologies S.A. make?
Over the twelve months to June 30, 2026 DBV Technologies S.A. reported revenue of $4.9M. That is 27.1% more than a year earlier.
When did DBV Technologies S.A. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 16, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from August 14, 2026.
Similar companies
Compare DBVT with
Follow DBVT
Get an email when DBV Technologies S.A. files with the SEC: results, executive changes, material agreements and annual reports.
Follow DBVT: get an email when it filesWhere the numbers come from
Financial figures are the values DBV Technologies S.A. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.